Reduced septal glucose metabolism predicts response to cardiac resynchronization therapy

Birnie, David H.; Kemp, Robert A. de; Tang, Antony; Ruddy, T; Gollob, Michael H.; Guo, Ann; Williams, Kathryn; Thomson, K.; DaSilva, Jean N.

doi:10.1007/s12350-011-9483-8

Cited by 15 publications

(5 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In clinical studies, patients fast for a minimum of 6 h before scanning, with nondiabetic patients receiving an oral glucose load before 18 F-FDG injection and diabetic patients an insulineuglycemic clamp to ensure that baseline blood glucose levels are not significantly different (30)(31)(32). Kreissl et al (13) found that as in humans, fasting reduced cardiac 18 F-FDG uptake rates in mice by approximately 5-to 6-fold.…”

Section: Discussionmentioning

confidence: 99%

Repeatable Noninvasive Measurement of Mouse Myocardial Glucose Uptake with ¹⁸F-FDG: Evaluation of Tracer Kinetics in a Type 1 Diabetes Model

et al. 2013

Self Cite

View full text Add to dashboard Cite

A noninvasive and repeatable method for assessing mouse myocardial glucose uptake with 18 F-FDG PET and Patlak kinetic analysis was systematically assessed using the vena cava imagederived blood input function (IDIF). Methods: Contrast CT and computer modeling was used to determine the vena cava recovery coefficient. Vena cava IDIF (n 5 7) was compared with the left ventricular cavity IDIF, with blood and liver activity measured ex vivo at 60 min. The test-retest repeatability (n 5 9) of Patlak influx constant K i at 10-40 min was assessed quantitatively using BlandAltman analysis. Myocardial glucose uptake rates (rMGU) using the vena cava IDIF were calculated at baseline (n 5 8), after induction of type 1 diabetes (streptozotocin [50 mg/kg] intraperitoneally, 5 d), and after acute insulin stimulation (0.08 mU/kg of body weight intraperitoneally). These changes were analyzed with a standardized uptake value calculation at 20 and 40 min after injection to correlate to the Patlak time interval. Results: The proximal mouse vena cava diameter was 2.54 6 0.30 mm. The estimated recovery coefficient, calculated using nonlinear image reconstruction, decreased from 0.76 initially (time 0 to peak activity) to 0.61 for the duration of the scan. There was a 17% difference in the image-derived vena cava blood activity at 60 min, compared with the ex vivo blood activity measured in the g-counter. The coefficient of variability for Patlak K i values between mice was found to be 23% with the proposed method, compared with 51% when using the left ventricular cavity IDIF (P , 0.05). No significant bias in K i was found between repeated scans with a coefficient of repeatability of 0.16 mL/min/g. Calculated rMGU values were reduced by 60% in type 1 diabetic mice from baseline scans (P , 0.03, ANOVA), with a subsequent increase of 40% to a level not significantly different from baseline after acute insulin treatment. These results were confirmed with a standardized uptake value measured at 20 and 40 min. Conclusion: The mouse vena cava IDIF provides repeatable assessment of the blood time-activity curve for Patlak kinetic modeling of rMGU. An expected significant reduction in myocardial glucose uptake was demonstrated in a type 1 diabetic mouse model, with significant recovery after acute insulin treatment, using a mouse vena cava IDIF approach.

show abstract

Section: Discussionmentioning

confidence: 99%

Repeatable Noninvasive Measurement of Mouse Myocardial Glucose Uptake with ¹⁸F-FDG: Evaluation of Tracer Kinetics in a Type 1 Diabetes Model

et al. 2013

Self Cite

View full text Add to dashboard Cite

show abstract

“…21,31,32 This pattern has been observed early post-revascularization following AMI. 31 40 nonischemic cardiomyopathy, repetitive stunning, may be observed after post-MI revascularization 31 Anselm et al described that the reverse mismatch pattern was seen in 48% of patients who underwent early PCI, with perfusion-FDG PET performed in the first 10 days following revascularization. 31 They observed that reverse mismatch was more associated to regional wall motion abnormalities and was associated with shorter time to PCI.…”

Section: Flow-metabolism Patterns Post-infarction In Petmentioning

confidence: 99%

Microvascular function, is there a link to myocardial viability: Is this another piece to the puzzle?

Erthal

Aleksova

Chong

et al. 2017

Journal of Nuclear Cardiology

View full text Add to dashboard Cite

“…Это, вероятнее всего, связано с высокой разрешающей способностью данного метода и большей чувствительностью 18 F-ФДГ в идентификации жизне-способного миокарда. Так, перфузионно-метаболиче-ское исследование миокарда при помощи ПЭТ с хлори-дом 82 Rbи 18 F-ФДГ [14] продемонстрировало хорошую информативность (AUC=0,855, р=0,017) в прогнозе ответа на КТР у пациентов с ДКМП. Научной группой Hacker [15] установлено, что объем жизнеспособного миокарда, по данным ПЭТ с 18F-ФДГ, является пре-диктором эффективности КРТ с чувствительностью 83% и специфичностью 71% при значении дефекта метаболизма 9% (площадь под ROC кривой 0,88; p=0,007).…”

Section: результатыunclassified

Metabolism of Fatty Acids in Left Ventricle Myocardium and the Efficacy Prognosis of Cardio-Resynchronizing Therapy in Dilated Cardiomyopathy Patients

Гуля¹,

Лишманов²,

Завадовский³

et al. 2014

Russ J Cardiol

View full text Add to dashboard Cite

Цель. Изучить состояние перфузии и метаболизма миокарда ЛЖ у пациентов с дилатационной кардиомиопатией (ДКМП) и разработать на этой основе гамма-сцинтиграфические предикторы эффективности кардиоресинхронизи-рующей терапии (КРТ). Материал и методы. В исследование включены 63 пациента с ДКМП (41 мужчина, 22 женщины) средний возраст -55,4±8,3 лет, с хронической сердеч-ной недостаточностью (ХСН) III-IV функционального класса по NYHA. До КРТ всем пациентам была выполнена сцинтиграфия миокарда с 99m Тс-МИБИ (для оценки миокардиальной перфузии) и с 123 I-ФМПДК (для оценки метаболизма жирных кислот в миокарде). До и через 6 месяцев после КРТ всем пациентам была выполнена ЭхоКГ для оценки внутрисердечной гемодинамики. Результаты. Через 6 месяцев после КРТ все пациенты были подразде-лены на две группы: 1) КСО ЛЖ уменьшился ≥15% (n= 39) -"респондеры" и 2) КСО ЛЖ уменьшился <15% (n=24) -"нереспондеры". До КРТ по пока-зателям насосной функции ЛЖ группы достоверно не различались. Досто-верная разница между группами была выявлена по следующим доопера-ционным сцинтиграфическим параметрам: дефект перфузии (ДП) (9,22±5,06% и 12,5±4,22%, p<0,01), дефект метаболизма на ранних изо-бражениях (ДМр) (9,21±5,42% и 11,27±5,39%, p<0,01). Получено уравне-ние множественной регрессии, позволяющее прогнозировать динамику конечно-систолического объема после КРТ. По данным ROC анализа наи-лучшую значимость в прогнозе эффективности КРТ имеет размер дефекта метаболизма миокарда и расчётное значение динамики конечно-систоли-ческого объема. Наилучшее пороговое значение ДМр=7,35% позволяет говорить об эффективности КРТ с чувствительностью и специфичностью 77,8% и 66,7%, соответственно. Наилучшее пороговое значение расчет-ной динамики конечно-систолического объема -34,02 позволяет гово-рить об эффективности КРТ с чувствительность и специфичностью 87,5% и 100%, соответственно.Заключение. Данные, полученные при выполнении метаболической гамма-сцинтиграфии миокарда могут быть использованы в комплексе методов, позво-ляющих прогнозировать эффективность кардиоресинхронизирующей терапии. Aim. To study perfusion and metabolism of LV myocardium in patients with dilated cardiomyopathy (DCMP) and to invent on this basement a gamma-specific predictors for cardio-resynchronizing therapy (RT) efficacy. Material and methods. Totally 63 patients with DCMP included (41 male, 22 female) with mean age 55,4±8,3 y. o., having congestive heart failure (CHF) of III-IV NYHA. Before RT all patients underwent scintigraphy of myocardium with 99m Тс (for perfusion assessment) and 123 I (for fatty acids metabolism). Before and in 6 months after RT all patients underwent echocardiography to assess intracardiac hemodynamics. Results. In 6 months after RT all patients were divided into two groups: 1) EDV LV decreased by ≥15% (n= 39) -"responders", and 2) ESV LV decreased <15% (n=24) -"non-responders". Before RT groups did not significantly differ by pumping function of the ventricle. Significant difference was found by following pre-operational scintigraphic parameters: perfusion ...

show abstract

Reduced septal glucose metabolism predicts response to cardiac resynchronization therapy

Abstract: In patients with non-ischemic cardiomyopathy, greater extent of septal glucose metabolic R-MM pattern, predicted response to CRT. This parameter may be useful for identifying patients who benefit from CRT.

Cited by 15 publications

References 41 publications

Repeatable Noninvasive Measurement of Mouse Myocardial Glucose Uptake with ¹⁸F-FDG: Evaluation of Tracer Kinetics in a Type 1 Diabetes Model

Repeatable Noninvasive Measurement of Mouse Myocardial Glucose Uptake with ¹⁸F-FDG: Evaluation of Tracer Kinetics in a Type 1 Diabetes Model

Microvascular function, is there a link to myocardial viability: Is this another piece to the puzzle?

Metabolism of Fatty Acids in Left Ventricle Myocardium and the Efficacy Prognosis of Cardio-Resynchronizing Therapy in Dilated Cardiomyopathy Patients

Contact Info

Product

Resources

About

Reduced septal glucose metabolism predicts response to cardiac resynchronization therapy

Abstract: In patients with non-ischemic cardiomyopathy, greater extent of septal glucose metabolic R-MM pattern, predicted response to CRT. This parameter may be useful for identifying patients who benefit from CRT.

Cited by 15 publications

References 41 publications

Repeatable Noninvasive Measurement of Mouse Myocardial Glucose Uptake with 18F-FDG: Evaluation of Tracer Kinetics in a Type 1 Diabetes Model

Repeatable Noninvasive Measurement of Mouse Myocardial Glucose Uptake with 18F-FDG: Evaluation of Tracer Kinetics in a Type 1 Diabetes Model

Microvascular function, is there a link to myocardial viability: Is this another piece to the puzzle?

Metabolism of Fatty Acids in Left Ventricle Myocardium and the Efficacy Prognosis of Cardio-Resynchronizing Therapy in Dilated Cardiomyopathy Patients

Contact Info

Product

Resources

About

Repeatable Noninvasive Measurement of Mouse Myocardial Glucose Uptake with ¹⁸F-FDG: Evaluation of Tracer Kinetics in a Type 1 Diabetes Model

Repeatable Noninvasive Measurement of Mouse Myocardial Glucose Uptake with ¹⁸F-FDG: Evaluation of Tracer Kinetics in a Type 1 Diabetes Model